Oncternal Therapeutics (ONCT) Expected to Announce Earnings on Thursday

Oncternal Therapeutics (NASDAQ:ONCT) is expected to release its earnings data after the market closes on Thursday, March 6th. Analysts expect Oncternal Therapeutics to post earnings of ($2.96) per share and revenue of $0.28 million for the quarter.

Oncternal Therapeutics Stock Performance

ONCT stock opened at $0.53 on Wednesday. The firm has a 50 day moving average price of $0.53 and a 200-day moving average price of $1.32. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $10.27. The firm has a market capitalization of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Oncternal Therapeutics in a research report on Monday. They issued a “hold” rating on the stock. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.